Dr. Gerami Donyel Seitzman, MD

Dr. Seitzman practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Seitzman's NPI, 1326081977, was assigned on June 13, 2006. Dr. Seitzman graduated from University Of Michigan Medical School in 1999. Dr. Seitzman holds California license A82640.

Dr. Seitzman's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Seitzman's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Seitzman to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Seitzman practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Seitzman's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Seitzman is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Seitzman's licenses on file in 3 states: California, Maryland and Michigan.

Dmand AI lists cataract, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Seitzman treats.

CMS data shows 358 Medicare services from Dr. Seitzman across 7 procedure codes in 2024, for 158 Medicare patients. Medicare paid $31,714 for them. Every service was in an office.

CMS counts 158 Medicare patients who saw Dr. Seitzman in 2024. The largest group is 65 to 74, with 60 patients. 65% of them have high cholesterol, and 59% have high blood pressure. 26% are also on Medicaid. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Seitzman's median patient age at 70, with 63% women.

In 2024, Dr. Seitzman wrote 397 Medicare Part D claims for 103 patients. 81% of them were for generic drugs. CMS names the drug for 305 of them, across 13 drugs with 11 or more claims each, at $20,774 in total drug cost. In 2023, CMS named 316 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Seitzman for performance year 2024, reported as part of a group. Dr. Seitzman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 94 papers to Dr. Seitzman, published from 2009 to 2025. 2022 was the busiest year, with 13. The most frequent topics are Conjunctivitis, High-Throughput Nucleotide Sequencing and COVID-19. Dr. Seitzman has published most often in Cornea. Dr. Seitzman's most frequent co-authors are Thomas M. Lietman, MD, Thuy Doan, MD and Jeremy David Keenan, MD.

Dmand AI links Dr. Seitzman to 5 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Acanthamoeba Keratitis, Conjunctivitis, Bacterial and Herpes Zoster Ophthalmicus. University of California, San Francisco sponsors the most, 2.

CMS Open Payments shows 47 general payments to Dr. Seitzman from 4 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 78% of the total. Kedrion Biopharma, Inc. paid the most, $63,613.

Dmand AI lists 2 awards for Dr. Seitzman.

Dr. Seitzman graduated from University Of Michigan Medical School in 1999. Dr. Seitzman is a member of AAO.

Dr. Seitzman is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.